Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Comment by MrMugsyon Jun 07, 2022 10:06pm
343 Views
Post# 34738984

RE:RE:RE:More Share Bought by Profound Medical's management

RE:RE:RE:More Share Bought by Profound Medical's management
BuenaSuertaAtod wrote:
MrMugsy wrote:
Charlie263 wrote: It's important to note that following purchases has been made in the month of May 2022:
Arun Menawat puchased 60516 shares, in addition to his previous puchases in Mar 2022
Brian Ellacott purchased 50000 shares
Ken Knudson Purchased 8000 shares.

It seems Profound medical's team did spectecular presentations of TULSA PRO at AUA. To me it seems, the rise of Profound Medical is imminent. 



Should be imminent - very much tied to hospitals, reimbursement and a permanent reimbursement code.


In the Q2 conf call they indicated that the lack of a permanent reimbursement code was not holding them back in any significant way. That's a good thing considering that they said then they were targeting Q4 2022 to apply for a permanent code, with Jan 2024 being the target date for actually having a permanent code.

How much difference does a permanent reimbursement code make? I can't quantify that myself. I know that getting the code would be an important positive milestone. But they've been treating patients for many months without one.



Covid was holding them back via implementing the hospitals - not the reimbursement code.

But what I'm talking about is their growth rate.  The permanent code is key to the growth rate in the future. 

When Profound started in the USA, they didn't have a code (or even the use of a temporary) so the initial patients were all out of pocket.

Then hospitals started using an existing code and I think Arun said some hospitals were getting $4K-$7K coverage for their operations and the rest was out of pocket.  Don't quote me on the number as I'm only going by memory.

The code is all about greater coverage and less out-of-pocket.  At that point, you are looking a much larger population for the procedure due to greater coverage.

The code is extremely important but it wasn't holding back recent roll-out.

Hope that makes it clearer.
<< Previous
Bullboard Posts
Next >>